Advertisement

Tardive Dyskinesia: Treatment Update

  • Divya Arya
  • Tarannum Khan
  • Adam J. Margolius
  • Hubert H. FernandezEmail author
Movement Disorders (T. Simuni, Section Editor)
  • 2 Downloads
Part of the following topical collections:
  1. Topical Collection on Movement Disorders

Abstract

Purpose of Review

Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of life. We evaluated peer-reviewed recently published articles with a goal of providing a critically appraised update on the latest advancements in this field.

Recent Findings

In 2017, FDA approved VMAT2 inhibitors, deutetrabenazine and valbenazine. They have demonstrated efficacy in several class 1 studies. Also there have been update in the evidence-based guidelines for treatment for tardive dyskinesia.

Summary

Various medication classes are being used for treatment of TD with VMAT2 inhibitors to be first FDA-approved medications. Their use should be tailored to the individual patient. Long-term studies will further guide us in how to optimize treatment, especially in the real-world setting. As clinicians, we need to take into consideration all aspects of symptomatology, etiology, potential side effects of the medications, to find the best possible “match” for our patients.

Keywords

Tardive dyskinesia Antipsychotics VMAT2 inhibitors Antioxidants Vitamins Neuroleptic-induced movements disorders 

Notes

Compliance with Ethical Standards

Conflict of Interest

Divya Arya, Tarannum Khan, and Adam J. Margolius each declare no potential conflicts of interest. Hubert H. Fernandez has received research support from Acorda Therapeutics, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Sunovion, but has no owner interest in any pharmaceutical company. Dr. Fernandez has received honoraria from American Osteopathic Association, Cleveland Clinic, South Alabama Medical Science Foundation Thoraxx Clinical Communications, UMA Education, as a speaker in CME events. Dr. Fernandez has received honoraria from Acorda Therapeutics, Denali Therapeutics, Pfizer, Partners Healthcare System(Parkinson Study Group), Sunovion Research and Development Trust as a consultant. Elsevier as the Editor-In-Chief of Parkinsonism and Related Disorders Journal. Dr. Fernandez has received royalty payments from Demos Publishing and Springer for serving as a book author/editor. The Cleveland Clinic has a contract with Teva for Dr. Fernandez’ role as a Co-Principal Investigator in SD-809/Austedo Tardive Dyskinesia global studies. Dr. Fernandez also serves as a member of the publication committee for Acorda Pharmaceuticals, Sunovion Pharmaceuticals but does not receive any personal compensation for this.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. New York: Raven press; 1995. p. 1485–96.Google Scholar
  2. 2.
    Sigwald J, Bottier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l’evolution prolongee secondaire a un traitement par les neuroleptiques. Rev Neurol ( Paris ). 1959;100:751–5.Google Scholar
  3. 3.
    Faurbye A, Rasch P, Petersen PB, G. B, Pakkenberg H. Neurological symptoms in pharmagotherapy of psychoses. Acta Psychiatr Scand. 1964;40:10–27.  https://doi.org/10.1111/j.1600-0447.1964.tb05731.x.PubMedGoogle Scholar
  4. 4.
    Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Ward. Neurology and Therapy Volume: 7 Issue 2 (2018) ISSN: 2193–8253 Online ISSN: 2193–6536 ane, 1995.Google Scholar
  5. 5.
    Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018 Jun 15;389:10–6.  https://doi.org/10.1016/j.jns.2018.02.008.PubMedGoogle Scholar
  6. 6.
    Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Jensen N, Oliveira JRM. Basal ganglia vulnerability to oxidative stress. Front Neurosci. 2014;8:80.  https://doi.org/10.3389/fnini.2014.00080.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Martins MR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL, Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox Res. 2008;13(1):63–9.PubMedGoogle Scholar
  9. 9.
    Casey DE, Gerlach J, Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376–9.PubMedGoogle Scholar
  10. 10.
    Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48 viii.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardivedyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–7 Review.PubMedGoogle Scholar
  12. 12.
    Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr OpinPsychiatry. 2008;21(2):151–6.  https://doi.org/10.1097/YCO.0b013e3282f53132 Review.Google Scholar
  13. 13.
    Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(Suppl 4):12–9.PubMedGoogle Scholar
  14. 14.
    Fountoulakis KN, Tegos T, Kimiskidis V. Lithium monotherapy-induced tardive dyskinesia. J Affect Disord. 2019;244:78–9.  https://doi.org/10.1016/j.jad.2018.10.094.PubMedGoogle Scholar
  15. 15.
    Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995;31(2):259–64.PubMedGoogle Scholar
  16. 16.
    Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry. 1994;28(2):328–30.PubMedGoogle Scholar
  17. 17.
    Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996;47(9):991–3.  https://doi.org/10.1176/ps.47.9.991.PubMedGoogle Scholar
  18. 18.
    52.Raveendranathan D, Rao SG. Sertraline induced acute mandibular dystonia. J Neurosci Rural Pract. 2015;6(4):586–7.  https://doi.org/10.4103/0976-3147.169804.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–9.  https://doi.org/10.1111/j.1365-2036.2009.04189.x.PubMedGoogle Scholar
  20. 20.
    Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache. 2016;56(1):153–61.  https://doi.org/10.1111/head.12712.PubMedGoogle Scholar
  21. 21.
    Madruga-Garrido M, Mir P. Tics and other stereotyped movements as side effects of pharmacological treatment. Int Rev Neurobiol. 2013;112:481–94.  https://doi.org/10.1016/B978-0-12-411546-0.00016-0.PubMedGoogle Scholar
  22. 22.
    Clark BG, Araki M, Brown HW. Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982;11(4):435.  https://doi.org/10.1002/ana.410110423.PubMedGoogle Scholar
  23. 23.
    Osifo NG. Drug-related transient dyskinesias. Clin Pharmacol Ther. 1979;25(6):767–71.PubMedGoogle Scholar
  24. 24.
    Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3.  https://doi.org/10.7916/d88p5z71.
  25. 25.
    Tenback DE, Bakker PR, van Harten PN. Risk factors for tardive movement disorders in schizophrenia [in Dutch]. Tijdschr Psychiatr. 2015;57(2):120–4.PubMedGoogle Scholar
  26. 26.
    Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–80.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Guy W. ECDEU assessment manual of psychopharmacology Washington, DC: US department of health, Education and welfare. 1976.Google Scholar
  28. 28.
    Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2–3):247–65 Epub 2005 Apr 18. Erratum in: Schizophr Res. 2006 Jul; 85(1–3):305.PubMedGoogle Scholar
  29. 29.
    Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64(2):171–9.PubMedGoogle Scholar
  30. 30.
    •• Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9.  https://doi.org/10.1212/WNL.0b013e31829d86b6 Review. Erratum in: Neurology. 2013 Nov 26; 81(22):1968. This article tells about the level of efficacy of miscellaneous treatments for the TD. PubMedGoogle Scholar
  31. 31.
    •• Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75.  https://doi.org/10.1016/j.jns.2018.02.010 Epub 2018 Feb 5. Review. Bhidayasiri R et al in 2018 published the algorithms that can help physicians to go step by step to figure about the treatment. PubMedGoogle Scholar
  32. 32.
    Semin Neurol. 2007 Apr; 27(2):159-69. Tardive dyskinesia. Soares-Weiser K1, Fernandez HH.Google Scholar
  33. 33.
    Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601–16.  https://doi.org/10.1016/B978-0-444-52014-2.00043-4 Review.PubMedGoogle Scholar
  34. 34.
    Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;21(Pt11):2053–66.Google Scholar
  35. 35.
    Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010;10(6):893–901.  https://doi.org/10.1586/ern.10.58 Review>.PubMedGoogle Scholar
  36. 36.
    Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306.  https://doi.org/10.1186/s12888-018-1889-2 PubMed PMID: 30249218; PubMed Central PMCID: PMC6154822.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Margolese HC, Chouinard G, Kolivakis TT, Beau-clair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatr. 2005;50(11):703–14.Google Scholar
  38. 38.
    Mentzel TQ, van der Snoek R, Lieverse R, Oorschot M, Viechtbauer W, Bloemen O, et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry. 2018;79(6):pii: 17r11852.  https://doi.org/10.4088/JCP.17r11852.Google Scholar
  39. 39.
    Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56 Review.PubMedGoogle Scholar
  40. 40.
    Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014;73:89–97.  https://doi.org/10.1016/j.neuint.2013.12.003 Epub 2014 Jan 4. Review. PubMed PMID: 24398404; PubMed Central PMCID: PMC5028832.PubMedPubMedCentralGoogle Scholar
  41. 41.
    • Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychi-atry. 2017;174(5):476–84. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. Google Scholar
  42. 42.
    • Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia. J Clin Psy-chiatry. 2017;78(9):1344–50. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. Google Scholar
  43. 43.
    • Ingrezza [package insert]. San Diego: Neurocrine Biosciences; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. Google Scholar
  44. 44.
    • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoja¨rvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedGoogle Scholar
  45. 45.
    • Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–10. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralGoogle Scholar
  46. 46.
    • AUSTEDO [package insert]. North Wales: Auspex Pharmaceuticals; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. Google Scholar
  47. 47.
    • Fernandez, et al. Long-term safety and efficacy of deutetrabenazine for treatment of tardive dyskinesia. JNNP. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. Google Scholar
  48. 48.
    • Solmi M, Pigato, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–38. This reference gives us insight about use of new VMAT 2 inhibitors—valbenazine and deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralGoogle Scholar
  49. 49.
    Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind,placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615–21.  https://doi.org/10.4088/JCP.09m05125yel Epub 2010 Sep 21.PubMedGoogle Scholar
  50. 50.
    Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry. 1999;56(9):836–41.  https://doi.org/10.1001/archpsyc.56.9.836.PubMedGoogle Scholar
  51. 51.
    Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;(2):Art. No.: CD000209.  https://doi.org/10.1002/14651858.CD000209.pub2.
  52. 52.
    Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93.PubMedGoogle Scholar
  53. 53.
    Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51.PubMedGoogle Scholar
  54. 54.
    Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology. 1978;56(2):145–51.PubMedGoogle Scholar
  55. 55.
    Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–5.PubMedGoogle Scholar
  56. 56.
    Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000204.PubMedGoogle Scholar
  57. 57.
    Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treattardive dyskinesia. Neurology. 2016;86(7):651–9.  https://doi.org/10.1212/WNL.0000000000002370 Epub 2016 Jan 20. PubMed PMID: 26791148.).PubMedGoogle Scholar
  58. 58.
    Van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7.PubMedGoogle Scholar
  59. 59.
    Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352–5.PubMedGoogle Scholar
  60. 60.
    Kañovský P, Streitová H, Bares M, Hortová H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of long-lasting effect. Mov Disord. 1999;14(5):886–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Divya Arya
    • 1
  • Tarannum Khan
    • 1
  • Adam J. Margolius
    • 2
  • Hubert H. Fernandez
    • 2
    Email author
  1. 1.Pauline Braathen Neuroscince InstituteCleveland Clinic FloridaWestonUSA
  2. 2.Center for Neurological RestorationCleveland ClinicClevelandUSA

Personalised recommendations